When most people think about protein biomanufacturing, insulin is the story they know. And it’s a good story — a genuinely transformative one. The ability to produce human insulin in engineered bacteria, rather than extracting it from pig and cow pancreases, revolutionized diabetes care for hundreds of millions of people worldwide. It was biotechnology’s proof of concept, its moon landing moment, its demonstration that living cells could be turned into pharmaceutical factories. But here’s the thing about moon landings — they’re not the destination. They’re the beginning of something much larger.
We are now decades into the protein biomanufacturing era, and the technology has matured in ways that make insulin look like chapter one of a very long book. Recombinant protein production, cell-free synthesis, precision fermentation, and advanced mammalian cell culture systems have created manufacturing capabilities that can produce virtually any protein the human body makes — and many it doesn’t — with increasing efficiency and decreasing cost. The question that deserves more attention than it gets is this: which diseases, beyond the famous diabetes story, are sitting in the waiting room of protein biomanufacturing, ready to be transformed by the same basic principle that gave us recombinant insulin?
The answer is more surprising, more diverse, and more urgently important than most people realize.
Understanding What Protein Biomanufacturing Actually Does
Before we dive into specific diseases, let’s make sure we’re speaking the same language. Protein biomanufacturing is essentially the process of programming living organisms — bacteria, yeast, mammalian cells, or even plants — to produce specific proteins that have therapeutic value. The proteins your own body produces are extraordinary molecular machines. Enzymes catalyze critical biochemical reactions. Antibodies identify and neutralize threats. Hormones coordinate complex physiological processes. Clotting factors stop bleeding. Growth factors repair tissue. When any of these goes missing, malfunctions, or is needed in quantities the body cannot produce, disease follows.
The biomanufacturing revolution means we can now produce replacement or supplementary versions of these proteins outside the human body, at scale, with pharmaceutical precision. Think of it as building a spare parts factory for human biology. And like any factory, once the production infrastructure exists and the engineering challenges are solved, the marginal cost of adding new products to the line decreases significantly. The platform that makes insulin also makes erythropoietin. The infrastructure that produces monoclonal antibodies for cancer can be redirected toward rare genetic diseases. The same basic toolkit enables an expanding universe of applications.
Hemophilia: A Disease Already Transformed, Still Evolving
Hemophilia A and B — caused by deficiencies in clotting factors VIII and IX respectively — represent one of the clearest examples of what protein biomanufacturing can accomplish beyond insulin. Before recombinant clotting factors became available, people with hemophilia received plasma-derived factor concentrates that carried real risks of viral contamination. HIV devastated hemophilia communities in the 1980s through contaminated blood products. The transition to recombinant factor products, manufactured using biomanufacturing rather than human plasma, eliminated those viral contamination risks and dramatically improved treatment safety.
But the hemophilia story continues to evolve in ways that illustrate biomanufacturing’s expanding possibilities. Extended half-life factor products — engineered versions of clotting factors with modifications that allow them to remain active in the body for longer — have reduced treatment burden from multiple infusions per week to once weekly or even less frequent dosing. Emicizumab, a bispecifically engineered antibody that mimics factor VIII function, has transformed prophylactic treatment for hemophilia A including in patients with inhibitors — the most challenging patient population. Gene therapy approaches that could provide functional cures are advancing through clinical trials. The hemophilia field is essentially a living laboratory for how successive generations of protein biomanufacturing innovation can progressively improve outcomes for a disease community.
Lysosomal Storage Disorders: The Rare Disease Frontier
Here’s a category of diseases most people have never heard of that protein biomanufacturing is uniquely positioned to address. Lysosomal storage disorders are a group of approximately 50 rare inherited conditions caused by deficiencies in specific enzymes that normally function inside cellular compartments called lysosomes. Without these enzymes, waste products accumulate inside cells, causing progressive tissue damage affecting organs including the heart, brain, liver, spleen, and skeletal system. The specific disease depends on which enzyme is missing — Gaucher disease from glucocerebrosidase deficiency, Fabry disease from alpha-galactosidase A deficiency, Pompe disease from acid alpha-glucosidase deficiency, and dozens more.
Enzyme replacement therapy — manufacturing the deficient enzyme using biomanufacturing and infusing it into patients — has transformed several of these conditions from progressive fatal diseases into manageable chronic conditions. Imiglucerase for Gaucher disease, agalsidase for Fabry disease, alglucosidase alfa for Pompe disease — these are biomanufactured proteins that quite literally give patients their lives back. But here’s the frustrating reality: many of the fifty-plus lysosomal storage disorders still lack approved enzyme replacement therapies. The diseases are rare, the patient populations small, and commercial incentives for development weak. Protein biomanufacturing has the technical capability to address many more of these conditions than it currently does — what’s missing is investment and development prioritization, not scientific possibility.
Alpha-1 Antitrypsin Deficiency: An Underserved Patient Population
Alpha-1 antitrypsin deficiency is a genetic condition affecting approximately 100,000 people in the United States alone — a number that’s almost certainly an underestimate given how frequently the condition goes undiagnosed. The disease causes a deficiency of a protein called alpha-1 antitrypsin, which normally protects lung tissue from inflammatory damage by neutrophil elastase. Without adequate alpha-1 antitrypsin, lung tissue is progressively destroyed, causing emphysema even in non-smokers. The liver, which produces the deficient protein, can also be affected by accumulation of abnormally folded protein variants.
Augmentation therapy — infusing purified or recombinant alpha-1 antitrypsin to restore protective protein levels — is an obvious therapeutic approach, and plasma-derived augmentation products do exist. But recombinant versions manufactured through biomanufacturing remain an active development area, with the potential to produce more consistent, scalable, and potentially more effective protein than plasma-derived products. More importantly, there are serious questions about whether the available therapies are reaching all patients who could benefit. Alpha-1 antitrypsin deficiency is frequently misdiagnosed as asthma or COPD without underlying genetic testing, meaning many patients never receive appropriate augmentation therapy. Protein biomanufacturing has a role to play here — but so does diagnostic improvement.
Neurological Diseases and the Challenge of Brain Delivery
The nervous system represents both one of the most exciting and most challenging frontiers for protein biomanufacturing. Numerous neurological diseases involve deficiencies or dysfunctions of proteins critical to neural function — and the biomanufacturing toolkit can produce those proteins. The problem is getting them where they need to go. The blood-brain barrier is a formidable biological checkpoint that prevents most proteins from crossing from the bloodstream into brain tissue. It’s a security system evolved to protect the brain from pathogens and toxins, and it doesn’t discriminate between therapeutic proteins and threats.
Several creative approaches are being developed to overcome this. Some researchers are engineering therapeutic proteins with modifications that allow them to hitch a ride on transport systems that naturally cross the blood-brain barrier. Others are working on direct intrathecal delivery — injecting proteins directly into the cerebrospinal fluid that bathes the brain and spinal cord. Nusinersen, an oligonucleotide therapy for spinal muscular atrophy delivered intrathecally, demonstrated that direct nervous system delivery is clinically feasible, opening a pathway for protein therapeutics targeting neurological diseases.
Spinal Muscular Atrophy: A Disease Being Redefined
Spinal muscular atrophy deserves its own spotlight because it illustrates how protein biomanufacturing — in this case extended to include protein-replacement-adjacent approaches — can fundamentally redefine the prognosis of a devastating disease. SMA is caused by loss-of-function mutations in the SMN1 gene, resulting in deficiency of survival motor neuron protein. Without adequate SMN protein, motor neurons degenerate progressively, causing muscle weakness and, in the most severe forms, death in infancy.
The therapeutic revolution in SMA has been extraordinary. Nusinersen increases SMN protein production from a backup gene. Onasemnogene abeparvovec delivers a functional copy of the SMN1 gene. Risdiplam is a small molecule that modifies splicing of the backup gene to produce more functional protein. Children who would previously have died before age two are now reaching school age with near-normal motor development. This is not incremental progress — it’s the difference between death and life, between paralysis and walking. And it happened because the field correctly identified protein deficiency as the root cause and pursued multiple strategies to restore adequate protein levels.
Rare Metabolic Disorders: Hundreds of Conditions Waiting
Beyond lysosomal storage disorders lies a broader universe of rare metabolic conditions caused by enzyme deficiencies — phenylketonuria, maple syrup urine disease, propionic acidemia, methylmalonic acidemia, urea cycle disorders, and dozens more. These conditions collectively affect hundreds of thousands of people worldwide, and most of them are currently managed through highly restrictive dietary interventions rather than targeted enzymatic treatments.
Pegvaliase, an enzyme replacement therapy for phenylketonuria that uses a bacterial enzyme modified to reduce immune reactions, demonstrated that protein biomanufacturing can provide treatment options for metabolic conditions beyond dietary management. The success of this approach opens a conceptual door to similar enzyme replacement strategies for other metabolic disorders. The technical challenge is real — producing active enzymes, ensuring they reach their sites of action, and managing immune responses to non-human proteins requires substantial bioengineering — but it’s a challenge that falls squarely within protein biomanufacturing’s expanding capabilities.
Primary Immunodeficiency Diseases: Building Immune Systems
Immunoglobulin replacement therapy — infusing concentrated antibody preparations to replace or supplement deficient antibody production in patients with primary immunodeficiency diseases — is one of the less celebrated but genuinely life-transforming applications of protein biomanufacturing principles. Patients with conditions like common variable immunodeficiency, X-linked agammaglobulinemia, or specific antibody deficiency lack the ability to produce effective antibody responses. Without immunoglobulin therapy, recurrent and severe infections progressively damage their organs and significantly shorten their lives.
Current immunoglobulin products are derived from donated human plasma, which creates supply constraints and variability challenges. Recombinant immunoglobulin production — manufacturing specific antibody classes using biomanufacturing rather than extracting them from plasma — could provide more consistent, scalable, and potentially safer alternatives. More ambitiously, synthetic biology approaches to manufacturing highly specific antibody cocktails tailored to individual patients’ immunological profiles represent a longer-term aspiration that current platform capabilities are beginning to approach.
Chronic Inflammatory Diseases Beyond the Known Biologics
Rheumatoid arthritis, psoriasis, inflammatory bowel disease — these conditions have been transformed by biological therapies, particularly TNF inhibitors and IL-inhibitor antibodies. That’s the known story, and it’s a good one. But there are chronic inflammatory conditions that have received far less therapeutic attention from protein biomanufacturing, despite evidence that protein-mediated pathways drive their pathology.
Chronic spontaneous urticaria, eosinophilic esophagitis, hidradenitis suppurativa, systemic lupus erythematosus — these conditions affect millions of people with significant impact on quality of life, and while some biological therapies have been approved in recent years, the pipeline remains relatively thin compared to disease burden. As the understanding of specific cytokine and receptor pathways driving each condition deepens, protein biomanufacturing provides the toolkit to translate that biological understanding into targeted therapeutics. The challenge is prioritization and investment rather than fundamental scientific capability.
Rare Pulmonary Diseases: An Emerging Frontier
The lungs represent a particularly interesting target for protein biomanufacturing therapeutics because inhaled delivery provides a direct route that bypasses many of the systemic delivery challenges that complicate protein therapeutics elsewhere. Pulmonary arterial hypertension — a progressive, life-threatening condition involving abnormal vascular remodeling in the lung circulation — has seen several protein-based therapeutic approaches, including prostacyclin analogs and endothelin receptor antagonists. But the disease remains severely underserved, with treatments that manage rather than reverse its underlying pathology.
Idiopathic pulmonary fibrosis — progressive scarring of lung tissue with poor prognosis and limited treatment options — represents another condition where protein biomanufacturing approaches targeting the specific growth factors and cytokines driving fibrotic remodeling could offer meaningfully better therapies than currently available options. The biology of these conditions is being mapped with increasing precision, and that biological map is increasingly showing targets accessible to protein therapeutics.
Hemoglobinopathies: More Than Sickle Cell
Sickle cell disease and beta-thalassemia have received enormous attention from biotechnology, particularly gene therapy approaches. But the broader category of hemoglobinopathies — disorders affecting hemoglobin structure or production — includes conditions that receive far less therapeutic development attention. Pyruvate kinase deficiency, hereditary spherocytosis, and various forms of congenital dyserythropoietic anemia affect the red blood cell production process through different mechanisms, many involving protein deficiency or dysfunction that protein biomanufacturing could theoretically address.
Mitapivat, a small molecule activator of pyruvate kinase, demonstrated clinical benefit in pyruvate kinase deficiency — but a direct enzyme replacement approach using recombinant pyruvate kinase represents an alternative strategy that the biomanufacturing toolkit could pursue. The principle is the same as with lysosomal storage disorders: identify the missing or dysfunctional protein, manufacture a replacement version, and restore biochemical function. The technical challenges vary by condition, but the conceptual framework is consistent.
Fertility and Reproductive Medicine: An Underappreciated Application
Protein biomanufacturing already plays a significant role in reproductive medicine that doesn’t always receive recognition as biotechnology. Recombinant follicle-stimulating hormone and luteinizing hormone — produced through biomanufacturing rather than extracted from urine — have become standard components of assisted reproduction protocols. These recombinant gonadotropins offer more consistent dosing, eliminate concerns about infectious contamination from urinary-derived products, and have helped millions of couples achieve pregnancies that would otherwise have been impossible.
But there are further applications in reproductive medicine where protein biomanufacturing could expand its contribution. Recombinant anti-Müllerian hormone assays for ovarian reserve assessment are improving fertility evaluation. Research into proteins that support endometrial receptivity — critical for embryo implantation — is identifying potential therapeutic targets for recurrent implantation failure, one of the most frustrating and underserved challenges in reproductive medicine. The intersection of reproductive biology and protein biomanufacturing is likely to produce important new applications in the coming decade.
Wound Healing and Tissue Repair
The proteins that drive wound healing — growth factors like epidermal growth factor, fibroblast growth factor, vascular endothelial growth factor, and platelet-derived growth factor — are produced naturally by the body but in quantities that can be insufficient in certain clinical situations. Diabetic foot ulcers, chronic venous ulcers, pressure injuries, and burns represent wound healing challenges where the body’s own repair machinery is inadequate. Recombinant growth factor therapies — biomanufactured versions of the proteins that normally drive tissue repair — have shown clinical benefit and deserve expanded development and accessibility.
Becaplermin, a recombinant form of platelet-derived growth factor, has been approved for diabetic foot ulcers, demonstrating clinical proof of concept. But the category remains underdeveloped relative to the burden of chronic wounds, which affect millions of people globally and generate enormous healthcare costs. Diabetic foot disease alone is the leading cause of non-traumatic lower limb amputation worldwide — a devastating outcome that better biomanufactured wound healing therapies could help prevent.
The Manufacturing Cost Barrier Must Fall
Across all these disease areas, a common thread limits the reach of protein biomanufacturing: cost. Protein therapeutics are expensive to develop, expensive to manufacture, and expensive to administer. For rare diseases with small patient populations, the per-patient economics of development and manufacturing make pricing that covers costs inherently high. For common diseases in developing nations, even moderately priced protein therapeutics remain inaccessible.
Advances in fermentation efficiency, continuous manufacturing processes, cell-free protein synthesis, and plant-based biomanufacturing platforms are all working to push protein production costs downward. The trend line is encouraging — the cost of producing a gram of recombinant protein has fallen by orders of magnitude over the past three decades. Continuing that trajectory is essential to ensuring that the protein biomanufacturing toolkit can reach not just the diseases that affect wealthy populations but the full spectrum of conditions where therapeutic proteins could relieve suffering globally.
Conclusion
Insulin’s story is remarkable, but it was never meant to be the whole story. Protein biomanufacturing is a platform technology — a general-purpose capability that can be aimed at an expanding universe of diseases as biological understanding deepens and manufacturing capabilities mature. From lysosomal storage disorders to rare metabolic conditions, from pulmonary diseases to chronic inflammatory conditions, from hemoglobinopathies to wound healing challenges, the list of diseases standing to benefit from protein biomanufacturing extends far beyond what most people imagine when they think about biotechnology medicine. The barriers are real — cost, delivery challenges, investment prioritization, rare disease economics — but they are barriers to application, not barriers to possibility. The biological factory has been built.
FAQs
What makes protein biomanufacturing different from traditional pharmaceutical manufacturing?
Traditional pharmaceutical manufacturing typically produces small chemical molecules through chemical synthesis processes. Protein biomanufacturing uses living organisms — bacteria, yeast, or mammalian cells — programmed to produce specific proteins that are too large and complex to synthesize chemically. These proteins mimic or supplement natural biological molecules, making them uniquely suited to treating diseases caused by protein deficiency or dysfunction. The biological nature of the production process creates both extraordinary therapeutic precision and distinctive manufacturing challenges around consistency, stability, and cost.
Why do so many rare diseases still lack protein replacement therapies if the technology exists?
The primary barrier is economic rather than scientific. Developing a protein therapy requires hundreds of millions of dollars in research, clinical trials, and manufacturing infrastructure. For rare diseases affecting small patient populations, recovering those development costs requires very high per-patient pricing, which creates reimbursement challenges and limits market size. Many conditions lack therapies not because protein biomanufacturing couldn’t produce relevant proteins but because commercial incentives for development are insufficient. Orphan drug designations, research grants, and patient advocacy organizations help compensate for this market failure, but the gap between what’s technically possible and what’s commercially developed remains substantial.
How does the immune system affect protein replacement therapy effectiveness?
Immune responses to therapeutic proteins are a significant clinical challenge. When the body receives a protein it has never produced — either because of a complete gene deletion or because the protein is derived from a non-human source — the immune system may recognize it as foreign and generate neutralizing antibodies. These antibodies can reduce or eliminate therapeutic effectiveness and, in some cases, cause serious reactions. Bioengineering strategies to reduce protein immunogenicity — including humanization of non-human proteins, pegylation, and immune tolerance induction — are important areas of ongoing development that directly affect how widely protein therapies can be applied.
Could precision fermentation eventually make protein therapies affordable for developing nations?
Precision fermentation — using engineered microorganisms to produce specific proteins — has the potential to dramatically reduce protein production costs compared to mammalian cell culture systems currently used for many complex biologics. As fermentation technology matures and scales, production costs should continue falling. Organizations working specifically on low-cost biomanufacturing for global health applications are developing simplified production systems optimized for resource-limited settings. The trajectory is encouraging, but achieving truly global accessibility requires not just lower manufacturing costs but also regulatory capacity building, cold chain infrastructure development, and healthcare system strengthening in lower-income nations.
What role does genomic medicine play in identifying new targets for protein biomanufacturing?
Genomic medicine is dramatically accelerating the identification of diseases suitable for protein biomanufacturing intervention. Whole genome and exome sequencing is revealing the genetic basis of conditions previously classified as idiopathic — of unknown cause — identifying specific enzyme deficiencies, protein dysfunctions, and pathway disruptions that protein therapeutics could address. Population genomics studies are revealing the prevalence of protein deficiency conditions that were previously underdiagnosed. As the functional annotation of the human genome improves, the map of potential protein biomanufacturing targets expands correspondingly, suggesting that the diseases currently being treated represent a small fraction of those that could ultimately benefit from the technology.
Henry Jude writes about biotechnology and housing technology, focusing on the latest trends. He has 15 years of experience reporting on and analyzing advances in these fields. Holding both a BSc and an MSc in Biotechnology, he uses his scientific training to explain complex ideas clearly and show how new technologies can be applied in real life.
Leave a Reply